Before Congress cuts payment, it should identify who controls the money.
Physicians are highly visible at the point of care, but visibility is not economic control. They may initiate clinical services while insurers, government programs, manufacturers, corporate owners, benchmark designers, and claims-management systems determine prices, payment rules, market access, ownership, and retained revenue.
Healthcare cost policy should follow control—not merely visibility. Before assigning blame or imposing another payment cut, policymakers should ask who set the price, who built the benchmark, who adjudicated the claim, who owned the recipient, and who retained the money.
The issue in one sentence
Core Thesis
Economic scrutiny and cost containment should be directed toward the actors that exercise the greatest control over price formation, payment methodology, claims adjudication, ownership, and revenue capture—not simply toward the clinician most visible when care is delivered.
The case in 60 seconds
- Physicians initiate care, document services, and generate the claims that make spending visible.
- They generally do not set administered payment rates, construct payer benchmarks, adjudicate claims, determine pharmaceutical or device list prices, or control corporate revenue allocation.
- Federal physician-payment restraint has been broad, recurrent, automatic, and poorly aligned with practice-cost inflation.
- Restrictions applied to insurers, manufacturers, and device companies have often been narrower, later, product-selective, or reversible.
- Official language frequently describes physicians through waste and efficiency, while insurer and manufacturer policy is more often framed through access, stability, innovation, or certainty.
- The result is a recurring mismatch between the actor receiving scrutiny and the actor controlling price or retained revenue.
The five-question economic-attribution test
Before Congress, an agency, or a payer assigns blame or imposes a payment cut, it should answer five questions:
- Who set the price?
- Who built the benchmark?
- Who adjudicated the claim?
- Who owned the entity that was paid?
- Who retained the revenue?
Public-Facing Line
Clinical initiation is not economic control. Visibility is not economic control.
Why this matters
Cost policy becomes less accurate when it regulates the most visible participant rather than the actor with the greatest economic control. That mismatch can suppress professional payment without addressing the price-setting, benchmark, ownership, and adjudication mechanisms that determine how money moves through the system.
The distinction matters because “provider spending” is not the same as physician income. A claim may carry a physician identifier while revenue is retained by a hospital, insurer-owned group, private-equity-backed organization, management company, billing entity, or other corporate structure. Aggregate spending can also rise because of service volume and intensity even while the unit payment for physician work is compressed.
This is not an argument that physicians never contribute to spending growth. It is an argument that economic attribution should precede economic regulation.
The Scrutiny–Control Inversion
Definition
The Scrutiny–Control Inversion occurs when economic scrutiny and cost containment are directed primarily toward the actor most visible at the point of care rather than toward the actors exercising the greatest control over price formation, payment methodology, market access, and revenue capture.
The three-ledger framework
The research organizes federal healthcare cost policy into three linked ledgers:
Who receives the cuts?
Tracks payment reductions, freezes, inflation-insensitive updates, sequestration, budget-neutrality adjustments, and other recurring restraint.
Who controls and captures the money?
Tracks price-setting power, benchmark construction, claims adjudication, ownership, market access, and the entity that ultimately retains revenue.
Who receives the blame?
Examines how official communications frame physicians, insurers, and manufacturers when explaining cost policy.
What the research found
Evidence Summary
The study reports a convergent descriptive pattern across the major federal policies examined. These findings support the proposed construct; they do not establish coordinated intent or prove that political spending caused the policy outcomes.
Physician payment restraint
- Medicare Physician Fee Schedule updates increased approximately 14% from 2000 through 2023, while the Medicare Economic Index increased approximately 52%; through 2024, the comparison was approximately 14% versus 56%.
- The physician conversion factor declined from $38.2581 in 2001 to approximately $33.40–$33.57 in 2026.
- The restraint was described as broad, budget neutral, recurring, and comparatively insensitive to inflation, although temporary congressional relief and recurring valuation adjustments occurred.
Corporate-sector policy
- The medical-device excise tax and health-insurer fee were repealed.
- Drug-price negotiation under the Inflation Reduction Act began with 10 products taking effect in 2026—a substantive policy change, but still recent and product-selective.
- Medicare Advantage payments increased 5.06% for 2026 despite MedPAC estimates of $76–$84 billion above fee-for-service equivalence.
Corporate-sector policy
- International comparisons cited in the article found U.S. prescription-drug prices at 278% of prices in 33 peer countries overall and brand-originator gross prices at 422%.
- Claims adjudication, downcoding, repricing, denial, appeal, and payment timing can affect realized professional payment even when the underlying service is unchanged.
Official framing
- A small matched sample of CMS communications framed physician policy through waste and efficiency, insurer policy through access and stability, and manufacturer policy through innovation and certainty.
A recurring policy failure pattern
Clinical initiation is treated as price control.
Ordering or performing a service makes the physician visible, but it does not establish control over the administered price, payer benchmark, benefit design, or corporate revenue path.
Provider spending is treated as physician income.
The name on a claim does not necessarily identify the entity that owns the practice, receives the payment, or retains the revenue.
An outlier is treated as representative of a profession.
An extreme payment, charge, or arbitration result can be rhetorically powerful while revealing little about the distribution of ordinary cases or the ownership of the recipient.
Claims adjudication is treated as administrative friction rather than economic control.
Denials, downcoding, repricing, reversals, and payment delays shape realized prices and should be measured as part of cost policy.
Policy language applies unequal presumption.
Physicians may be discussed as sources of waste while other sectors are discussed through access, stability, innovation, and certainty—even when their control over price and revenue is greater.
Healthcare Governance position
Healthcare Governance supports an economic-attribution standard for federal healthcare cost policy. Before imposing a cut, publishing an outlier narrative, or assigning sector-wide blame, policymakers should identify the actor that controls price formation, benchmark design, claim adjudication, ownership, and retained revenue.
Cost policy should be proportionate to economic control. It should distinguish independent clinical practices from hospital-, insurer-, or private-equity-owned entities and from management, revenue-cycle, and arbitration businesses that may operate under provider-facing identifiers.
Recommended policy actions
Require economic attribution before cost containment
- Identify who set the relevant price or payment methodology.
- Identify who constructed the benchmark and whether it is government-administered, insurer-calculated, contract-derived, charge-based, cost-based, survey-based, or adjudicated.
- Identify who adjudicated the claim and who ultimately retained the revenue.
Separate clinicians from corporate ownership structures
- Distinguish independent physicians from hospital-employed, insurer-owned, private-equity-backed, and management-services arrangements.
- Do not attribute corporate or revenue-cycle behavior to an entire clinical profession without ownership data.
Require denominator disclosure for outlier claims
- Report the entity count, eligible population, full distribution, actual payments versus submitted charges, professional-payment share, ownership, and concentration.
Require benchmark provenance
- Disclose who created the benchmark, what data it contains, how it was updated, and what question it can legitimately answer.
- Do not present the qualifying payment amount as an independent market-clearing price without explaining its statutory and payer-calculated origins.
Measure claims-management friction
- Publish denial, downcoding, repricing, reversal, appeal, and payment-timing data.
- Identify automated or third-party systems and compensation tied to payment reductions or “savings.”
- Audit whether affiliated and independent practices experience materially different adjudication patterns.
Apply parallel policy language across sectors
- Use consistent evidentiary standards when describing physicians, insurers, manufacturers, hospitals, device companies, and corporate intermediaries.
Study international net-price parity
- Conduct matched-product comparisons of verified net drug and device prices in comparable high-income countries, with volume, access, launch-timing, and confidentiality safeguards.
Make physician payment inflation-sensitive
- Develop a stable update mechanism that reflects practice-cost inflation while preserving appropriate value, utilization, and quality safeguards.
Implementation options
- Direct GAO and MedPAC to perform an independently dual-coded census of major federal cost-containment policies from 2001 to the present.
- Require CMS to publish standardized claims-friction datasets and ownership-linked payment data.
- Commission a matched-product international net-price audit for pharmaceuticals and devices.
- Require clearer ownership and revenue-retention reporting across physician organizations and management structures.
- Apply the five-question economic-attribution test prospectively to major payment reforms and retrospective policy reviews.
What this position does not say
- It does not claim that physicians never affect utilization or healthcare spending.
- It does not argue that physician compensation is uniformly inadequate or that access has already collapsed.
- It does not deny legitimate provider-side outliers, billing abuse, or strategic use of adjudication systems.
- It does not claim that insurers, manufacturers, hospitals, or device companies face no regulation.
- It does not treat lobbying capacity as proof that policy outcomes were purchased.
- It does not claim coordinated intent or a single campaign against physicians.
- It does not establish patient-outcome effects from the payment architecture described.
- It does not propose abandoning utilization review, fraud control, value assessment, or clinical accountability.
Common objections and responses
“Physician spending still increased substantially.”
Total physician spending per beneficiary can rise because of volume, intensity, population need, and site-of-service changes even while unit payment is compressed. That is why the analysis separates payment rates from total spending and why economic attribution must identify the relevant mechanism.
“Physicians remain highly compensated and Medicare participation is stable.”
The argument is not based on physician poverty. It concerns whether payment restraint is directed toward the actor controlling price and revenue, whether updates are sustainable relative to practice costs, and whether the same policy standards are applied across sectors.
“Providers also exploit billing and arbitration systems.”
Some do. The appropriate response is ownership, concentration, denominator, and actual-payment disclosure—not attribution of corporate or revenue-cycle conduct to an undifferentiated physician category.
“Insurers and manufacturers face major regulation.”
They do. The comparison concerns breadth, automaticity, durability, reversibility, and inflation sensitivity—not the absence of regulation.
“Claims management is necessary to prevent waste and error.”
Yes. Necessary administrative functions can still affect realized prices. Measurement should distinguish appropriate review from systematic downcoding, repricing, delay, or unequal treatment.
“International reference pricing could reduce access or alter launch strategy.”
Those risks are real. The recommendation is a verified, matched-product net-price study with explicit access and market-response safeguards—not automatic adoption of a foreign price.
Use this argument
Claim
Healthcare cost policy should identify the actor that controls price, benchmark construction, claim adjudication, ownership, and retained revenue before assigning blame or imposing a payment cut.
Best supporting evidence
- The “Follow the Cuts” three-ledger analysis of payment restraint, revenue capture, and official blame, 2001–2026.
- The full legislative brief, “Follow the Cuts: Aligning Healthcare Cost Policy With Economic Control.”
- The one-page legislative summary and the underlying federal sources cited in the article.
Main caveat
The analysis is purposive rather than a systematic census and supports a descriptive construct. It does not establish coordinated intent, causal effects of political spending, or patient-outcome consequences.
Likely counter argument
Physicians initiate many services and therefore remain appropriate targets for cost containment.
Response
Clinical initiation can affect utilization, but it does not by itself establish control over the price, benchmark, adjudication system, ownership structure, or retained revenue. Policy should measure each mechanism separately.
One sentence
Before cutting physician payment, policymakers should identify who set the price, built the benchmark, adjudicated the claim, owned the recipient, and retained the money.
Physicians are visible because they diagnose, treat, document, and generate claims. But visibility is not economic control. Prices, benchmarks, claims adjudication, ownership, and retained revenue are often controlled elsewhere. Healthcare cost policy should therefore follow the money and the decision rights before assigning blame or imposing another cut.
Clinical initiation is not economic control. Visibility is not economic control.
What the research contributes
- Names the Scrutiny–Control Inversion as a policy construct.
- Introduces a three-ledger method: who receives the cuts, who controls and captures the money, and who receives the blame.
- Adds claims adjudication and international price dispersion to the analysis of payment control.
- Compares matched official rhetoric across physicians, insurers, and manufacturers.
- Uses an explicit evidence hierarchy and separates descriptive findings from causal claims.
What the research contributes
- Names the Scrutiny–Control Inversion as a policy construct.
- Introduces a three-ledger method: who receives the cuts, who controls and captures the money, and who receives the blame.
- Adds claims adjudication and international price dispersion to the analysis of payment control.
- Compares matched official rhetoric across physicians, insurers, and manufacturers.
- Uses an explicit evidence hierarchy and separates descriptive findings from causal claims.
Evidentiary boundary — do not overread it
The article is a purposive structured descriptive analysis, not a systematic census. The policies and sectors examined are not identical; the matched communications sample is small; the inventory was not independently dual-coded; and the analysis does not prove coordinated intent, lobbying causation, or patient-outcome effects. It supports a descriptive policy construct and a research agenda.
Related resources
Full legislative brief
Follow the Cuts: Aligning Healthcare Cost Policy With Economic Control
One-page summary
Follow the Cuts: Quick Legislative Summary
Research article
Follow the Cuts: The Scrutiny–Control Inversion in American Healthcare, 2001–2026
Related issue
Adjudicated Rate Index
Related issue
Expert Opinion Transparency
Related analysis
Visibility Is Not Control
Prepared from: “Follow the Cuts: The Scrutiny–Control Inversion in American Healthcare, 2001–2026: A Three-Ledger Analysis of Payment Restraint, Revenue Capture, and Official Blame”; “Follow the Cuts: Aligning Healthcare Cost Policy With Economic Control”; and the companion one-page legislative summary. Article publication details pending confirmation.
Downloads
Follow the Cuts | The Scrutiny–Control Inversion in American Healthcare
Before assigning blame or imposing a payment cut, policymakers should identify who set the price, built the benchmark, adjudicated the claim, owned the recipient, and retained the money.
